Redburn Atlantic analyst Jamie Clark lowered the firm’s price target on Iqvia (IQV) to $188 from $255 and keeps a Buy rating on the shares. Iqvia lacks the potential earnings upgrades from improved demand that are possible for Charles River (CRL) through 2025, as well as any upside from a strategic review, the analyst tells investors in a research note. However, the firm believes this is already reflected in Iqvia’s valuation. The company’s model “provides it with a sufficient cushion to grow through the short-term factors impacting the CRO segment,” contends Redburn.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- Citi places ‘downside 90-day short-term view’ on Iqvia
- Iqvia price target lowered to $190 from $210 at Mizuho
- Positive Outlook for IQVIA Holdings Driven by Resilient TAS, Strategic Capital Allocation, and R&D Strength
- Definitive Healthcare downgraded to Neutral from Buy at BTIG
- IQVIA Holdings: Strong Performance and Growth Potential Justify Buy Rating